期刊文献+

聚苯乙烯磺酸镧对腺嘌呤致大鼠慢性肾衰高磷血症的治疗作用 被引量:3

Effect of polystyrene sulphur lanthanum on hyperphosphatemia in rats with chronic renal failure induced by adenine
下载PDF
导出
摘要 目的:观察聚苯乙烯磺酸镧对腺嘌呤致大鼠慢性肾衰高磷血症的影响。方法:以Yokozawz方法诱发大鼠慢性肾衰,将造模成功动物随机分为聚苯乙烯磺酸镧1.500、0.750、0.375g·kg-1·d-1剂量组、阳性对照组(碳酸钙咀嚼片组)、模型对照组、正常对照组,连续用药22d。实验过程中观察动物一般状况、进食量、大小便情况,自给药开始后7、14、21d称取动物体重,观察体重变化。分别于给药10、21d自大鼠颈静脉取血检测血清BUN、Cr、磷、钙、钾,同时检测红细胞计数(RBC)、血红蛋白(Hb)、血小板计数(PLT)及红细胞压积(HCT)。给药22d处死大鼠,摘取双侧肾脏,称重计算肾脏系数并进行病理组织学检查。结果:聚苯乙烯磺酸镧1.500g·kg-1·d-1组给药21d血清磷为(2.47±0.38)mmol/L,钙磷乘积为6.6±0.6,与模型对照组比较差异有统计学意义(P<0.05)。结论:聚苯乙烯磺酸镧可降低腺嘌呤所致大鼠肾衰模型血清磷水平。 AIM: To observe the effect of polystyrene sulphur lanthanum on hyperphosphatemia in rat model with chronic renal failure induced by adenine. METHODS: Chronic renal failure of rats was induced by Yokozawz method through infusing adenine ( 0.3 g·kg^-1·d^-1 ) for 25 days, and then model rats were given polystyrene sulphur lanthanum ( 1. 500, 0. 750, 0. 375 g·kg^-1·d^-1 ) and positive drug for 22 days, and the adenine was given eontifiuously for another 10 days. During the experiment courses, the body weight, general status, appetite, urination and defecation were observed. And levels of BUN, Cr, P^3+, Ca^2+, K^+ RBC, Hb, PLT,and HCT in blood were monitored after the drug was given for 10 and 21 days. Rats were killed for kidney pathology and a quotient calculation. RESULTS: The polystyrene sulphur lanthanum at a dose of 1.500 g·kg^-1·d^-1 could reduce the phosphor level significantly, and there was obviously different from that of control model group ( P 〈 0.05). CONCLUTION: The polystyrene sulphur lanthanum can significantly reduce the phosphor level of rat with chronic renal failure induced by adenine.
出处 《中国临床药理学与治疗学》 CAS CSCD 2007年第5期530-534,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 聚苯乙烯磺酸镧 慢性肾功能衰竭 腺嘌呤 血磷 polystyrene sulphur lanthanum chronic renal failure adenine blood phosphor
  • 相关文献

参考文献7

二级参考文献42

共引文献144

同被引文献30

  • 1沈磊.抗高磷酸血症新药碳酸镧[J].药学进展,2005,29(6):286-287. 被引量:4
  • 2黄新忠,范亚平,蒋季杰.两种非铝非钙新型磷结合剂的药理与临床[J].国际泌尿系统杂志,2006,26(2):276-279. 被引量:4
  • 3苗华,洪虹,潘明明.聚苯乙烯磺酸镧治疗腺嘌呤性慢性肾衰竭动物模型钙磷代谢异常的实验研究[J].中国血液净化,2007,6(5):272-275. 被引量:5
  • 4Foley R N,Collins A J,Herzog C A,Ishani A,Kalra P A. Serum phosphorus levels associate with coronary atherosclerosis in young adults[J]. J Am Soc Nephrol, 2009,20 : 397-404.
  • 5Isakova T, Gutierrez O M, Chang Y, Shah A, Tamez H, Smith K,et al. Phosphorus binders and survival on hemodialysis[J]. J Am Soc Nephrol, 2009,20 : 388-396.
  • 6Hutchison A J. Improving phosphate-binder therapy as a way forward[J]. Nephrol Dial Transplant, 2004,19 (Suppl 1) : Ⅰ19-Ⅰ24.
  • 7Koiwa F,Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M,et al. Prospective randomized muhicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphataemia in hemodialysis patients in Japan[J]. Ther Apheresis Dial, 2005,9: 340-346.
  • 8Nikolov I G, Joki N, Maizel J, Lacour B, Drueke T B, Massy Z A. Pleiotropic effects of the non-calcium phosphate binder sevelamer[J]. Kidney Int Suppl,2006(105) :S16-S23.
  • 9Shantouf R, Budoff M J, Ahmadi N, Tiano J, Flores F, Kalantar- Zadeh K. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients[J]. Am J Nephrol, 2008,28 : 275-279.
  • 10Mitsopoulos E, Griveas I, Zanos S, Anagnostopoulos K, Giannakou A,Pavlitou A, et al. Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride[J]. Int Urol Nephrol, 2005,37 : 321-328.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部